Quantcast

Latest Buprenorphine Stories

2014-08-27 08:27:45

RALEIGH, N.C., Aug. 27, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the company will be hosting an investor and analyst event and simultaneous webcast on Friday, September 5, 2014. The event is scheduled for 12-2 pm ET in New York City. http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO At this event, BDSI senior management will discuss the commercialization and launch plan for BUNAVAIL and provide updates on the BEMA(®)...

2014-08-12 08:29:19

BEMA Buprenorphine on track for late 2014 or early 2015 NDA filing by partner Endo Pharmaceuticals RALEIGH, N.C., Aug. 12, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that along with its commercial partner, Endo Pharmaceuticals, engaged in a positive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding BEMA Buprenorphine for the management of pain severe enough to require daily, around-the-clock,...

2014-08-07 16:29:42

BUNAVAIL(TM) (buprenorphine and naloxone) buccal film (CIII) approved by FDA for the maintenance treatment of opioid dependence; US launch planned for late Q3 RALEIGH, N.C., Aug. 7, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's recent achievements and an...

2014-07-29 08:31:39

MELBOURNE, Australia, July 29, 2014 /PRNewswire/ -- -- Next phase of the TPM®/Oxymorphone clinical development program has commenced -- TPM®/Oxycodone Phase 2a trial to be conducted in Australia during Q4 2014 -- TPM®/Oxymorphone Phase 2 trial to be conducted in the United States in 1H 2015 Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), today provided updates on its opioid transdermal patch programs after its...

2014-07-22 12:29:33

PITTSBURGH, July 22, 2014 /PRNewswire/ -- Community Care Behavioral Health Organization today released guidelines for treatment and recovery practices involving the use of methadone, an opioid used to treat opioid addiction. The guidelines* - titled, "Supporting Recovery from Opioid Addiction: Community Care Best Practice Guidelines for Recovery-Oriented Methadone Maintenance" - are intended to provide direction for physicians, clinicians, agencies, and systems in the Community Care...

2014-07-22 08:31:15

RALEIGH, N.C., July 22, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that its Board of Directors has appointed Charles J. (Chuck) Bramlage and Dr. Barry I. Feinberg as members of the Board. http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO Mr. Bramlage is a veteran pharmaceutical industry executive with extensive experience in marketing, sales and other commercial functions. He is currently the Chief Executive Officer of...

2014-07-16 08:28:03

FDA also approves the use of two Butrans patches for dose adjustments in appropriate chronic pain patients STAMFORD, Conn., July 16, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced that the U.S. Food & Drug Administration (FDA) approved a new 7.5 mcg/hour dosage strength of Butrans(®) (buprenorphine) Transdermal System CIII. Five strengths of Butrans will now be available: 5 mcg/hour, 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour and 20 mcg/hour. The Butrans Transdermal System is also...

2014-07-10 08:27:14

First and only FDA approved naloxone product specifically indicated for emergency therapy in settings where opioids may be present. RICHMOND, Va., July 10, 2014 /PRNewswire/ -- Kaleo, a privately-held pharmaceutical company headquartered in Richmond, Virginia, today announced the United States (U.S.) commercial availability of EVZIO for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. EVZIO is not a...

2014-07-07 08:27:32

- Pre-NDA meeting scheduled with FDA in July DUBLIN and RALEIGH, N.C., July 7, 2014 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), and BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today positive top-line results from its pivotal Phase III efficacy study of BEMA buprenorphine in opioid-experienced patients. BEMA buprenorphine is being developed for the management of pain severe enough to require...

2014-07-03 23:01:24

Harbor Village Florida comments on on a study that reduces relapses from heroin. USA (PRWEB) July 03, 2014 Patients that begin treatment for heroin and opioid addiction during hospitalization that also receive outpatient treatment (medical and psychiatric) are 5x less likely to relapse, according to a recent report “Treating Addicted Patients During, After Hospitalization Reduces Relapse” (6/30). According to the report, the average bill for opioid and heroin-related treatment in 2013...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related